PO.TB04.03 · 肿瘤生物学
细胞因子补充以改善肿瘤类器官-免疫细胞共培养
Cytokine supplementation for improved tumoroid-immune cell co-culture
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
实体瘤的免疫疗法依赖于肿瘤微环境中免疫细胞与上皮肿瘤细胞之间的稳健结合。然而,能够在短期体外培养期间同时维持上皮细胞和肿瘤浸润免疫细胞活力的培养条件仍未得到充分界定。患者来源的肿瘤类器官是一种能够在体外重现癌细胞但缺乏肿瘤免疫细胞成分的多细胞类器官系统,可通过回添免疫细胞在体外研究肿瘤-免疫相互作用。为探索一种替代方法,即肿瘤和免疫细胞的短期共培养,我们优化了OncoPro™肿瘤类器官培养基,以在培养患者来源的解离肿瘤细胞(DTC)消化物期间促进免疫细胞存活和组成稳定性。初步研究表明,单独在OncoPro培养基中培养的健康供体PBMCs在5天后损失了约80%的存活细胞。一项包含13种细胞因子和生长因子的实验设计(DOE)筛选确定了在维持均衡免疫亚群的同时增强PBMC存活的组合。其中,IL-2、GM-CSF、IL-15、IL-4和BAFF成为候选者,它们在多个供体中相对于未补充培养基提高了PBMC细胞计数,并有助于将淋巴细胞、单核细胞、NK细胞、辅助性T细胞和细胞毒性T细胞的比例保持在基线10%以内。利用这一细胞因子组合清单,我们接下来评估了同时支持免疫(CD45⁺)和上皮(EpCAM⁺)细胞群的培养条件。在分区的DOE框架中评估了三位供体以控制供体变异性。我们评估了两种培养方式:一种是在铺加培养基前将细胞包封于Geltrex™ Flex基质中的包埋培养,另一种是将细胞铺于补充了Y-27632、2%(v/v)Geltrex Flex基质和细胞因子的OncoPro培养基中的悬浮培养,并在5天后通过流式细胞术进行分析。基于试管的解离比板内解离产量高约25%,而使用CountBright™绝对计数微球的基于微球的计数细胞术与流式染色前采用台盼蓝进行的计数一致性在约25%以内。悬浮培养有利于免疫细胞活力,而在Geltrex Flex基质中的包埋则适度改善了肿瘤类器官的回收率但降低了CD45⁺细胞的存活。在各供体中,补充IL-2、IL-15、GM-CSF和BAFF的培养实现了最高的总存活细胞回收率和最小的免疫组成变化。总之,这些结果建立了一种细胞因子优化的培养基,可在短期肿瘤类器官共培养期间增强免疫细胞的活力和稳定性,从而改善对微环境的建模,并促进对肿瘤-免疫相互作用和治疗反应的下游研究。
查看英文原文 English abstract
Immunotherapies for solid cancers rely on robust engagement between immune and epithelial tumor cells within the tumor microenvironment. However, culture conditions that simultaneously sustain epithelial and tumor-infiltrating immune cell viability during short-term ex vivo culture remain poorly defined. Patient-derived tumoroids, multicellular organoid systems that recapitulate cancer cells in vitro but lack the immune cell component of tumors, enable interrogation of tumor-immune interactions in vitro via addback of immune cells. To explore an alternative approach, namely short-term co-culture of tumor and immune cells, we optimized OncoPro™ Tumoroid Culture Medium to promote immune cell survival and composition stability during culture of patient-derived dissociated tumor cell (DTC) digests. Initial studies showed that healthy donor PBMCs cultured in OncoPro medium alone lost approximately 80% of viable cells after 5 days. A design of experiments (DOE) screen of 13 cytokines and growth factors identified combinations that enhanced PBMC survival while maintaining balanced immune subpopulations. Among these, IL-2, GM-CSF, IL-15, IL-4, and BAFF emerged as candidates that increased PBMC cell counts relative to non-supplemented medium across multiple donors and helped preserve lymphocyte, monocyte, NK, helper T, and cytotoxic T cell proportions within 10% of baseline. Using this list of cytokine cocktails, we next assessed culture conditions supporting both immune (CD45⁺) and epithelial (EpCAM⁺) cell populations in colorectal cancer DTCs. Three donors were evaluated in a blocked DOE framework to control for donor variability. We evaluated both embedded culture where cells were encapsulated in Geltrex™ Flex matrix before media overlay, as well as suspension culture where cells were plated in OncoPro medium supplemented with Y-27632, 2% (v/v) Geltrex Flex matrix, and cytokines, and analyzed after 5 days by flow cytometry. Tube-based dissociation yielded ~25% higher recovery than in-plate dissociation, and bead-based enumeration cytometry using CountBright™ absolute counting beads agreed within ~25% of Trypan Blue-based counts made prior to staining samples for flow cytometry. Suspension culture favored immune cell viability, whereas embedding in Geltrex Flex matrix modestly improved tumoroid recovery but reduced CD45⁺ cell survival. Across donors, cultures supplemented with IL-2, IL-15, GM-CSF, and BAFF achieved the highest total viable cell recovery and the lowest change in immune composition. Together, these results establish a cytokine-optimized medium that enhances immune cell viability and stability during short-term tumoroid co-culture, enabling improved modeling of the microenvironment and facilitating downstream studies of tumor-immune interactions and therapeutic response.
利益披露 Disclosure
S. Salen,
Thermo Fisher Scientific Employment.
C. D. Paul,
Thermo Fisher Scientific Employment, Stock.
S. Hawkins,
Thermo Fisher Scientific Employment.
M. R. Dallas,
Thermo Fisher Scientific Employment.
D. Kuninger,
Thermo Fisher Scientific Employment.